Printed From:

Lantus® Provides Proven HbA1c Control

The long-term landmark ORIGIN trial1

ORIGIN = Outcome Reduction with Initial Glargine Intervention

Study Design

A randomized study of patients with IFG and/or IGT or early T2DM and established CV disease or CV risk at baseline. Patients received either Lantus® (n=6264) titrated to a target FPG of ≤95 mg/dL or standard care (n=6273). Standard care patients remained on their original treatment, if applicable, at randomization. Additional agents could be added as needed per discretion of the investigator. Median follow-up: 6.2 years.1,2


No statistically significant differences between Lantus® and standard care in the co-primary endpoints. Similar results were observed between Lantus® and standard care for all-cause mortality.

From Lantus Prescribing Information.1
View Lantus® long-term CV safety data from the ORIGINS trial.
FPG = fasting plasma glucose; IFG = impaired fasting glucose; IGT = impaired glucose tolerance

References:

  1. Lantus Prescribing Information. August 2015.
  2. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, et al., ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia.
    N Engl J Med. 2012 Jul 26;367(4):319-28.
    doi: 10.1056/NEJMoa1203858.
    Epub 2012 Jun 11.

Proven HbA1c control

See how Lantus® provides effective, improved glycemic control in diabetes patients.

Lantus® Prescribing Information. August 2015.

Once-daily dosing

Lantus® is a once-daily, long-acting insulin.**

**Lantus® Prescribing Information. August 2015.

Demonstrated long-term CV safety

Lantus® is a basal insulin with demonstrated long-term CV safety data††

††
Including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure. No difference was observed between Lantus® and standard of care in overall incidence of CV death, nonfatal MI, or nonfatal stroke. No difference was observed between treatment groups for death of any cause.